查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1803595

全球實驗室食蟹猴市場（按研究類型、健康狀況、性別、最終用戶和疾病領域）：預測（2025-2030 年）

Experimental Cynomolgus Monkey Market by Research Type, Health Status, Gender, End-User, Disease Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年實驗室食蟹猴市場價值為 3.1601 億美元，預計 2025 年將成長至 3.3611 億美元，複合年成長率為 6.59%，到 2030 年將達到 4.6349 億美元。

主要市場統計數據
預測年份（2024年） 3.1601億美元
基準年（2025年） 3.3611億美元
預測年份（2030年） 4.6349億美元
複合年成長率（%） 6.59%

探索食蟹猴在臨床前研發中的重要作用，以推進藥物發現和安全評估流程

使用非人靈長類動物模型進行臨床前評估是確保新型療法安全性和有效性的基石。在現有動物物種中，食蟹猴與人類具有遺傳和生理學上的相似性，這使得研究人員能夠獲得支持臨床決策的轉化數據。它們的免疫反應特徵反映了人類生物學的關鍵方面，因此對於評估生技藥品、細胞療法和小分子藥物至關重要。此外，成熟的群體管理和標準化測試方案使全球實驗室能夠獲得可重複的結果。

分析重新定義食蟹猴研究並加速臨床前創新和合規性的關鍵技術和監管變化

創新技術和不斷發展的監管政策正在重塑臨床前研究範式，食蟹猴處於前沿。 CRISPR 等基因編輯工具和精準基因組表徵的發展，使得客製化疾病模型的開發成為可能，並為治療方法檢驗開闢了新的途徑。同時，高解析度成像技術和體內遙測技術正在促進生理反應的即時監測，減少對傳統侵入性技術的依賴。這些突破不僅提高了數據質量，也凸顯了對更人性化研究設計的承諾。

研究近期美國關稅對供應鏈動態、成本和監管適應的深遠影響

對進口非人靈長類動物樣本徵收高額關稅，使臨床前測試項目變得更加複雜。過去依賴現有供應鏈的研究機構面臨價格波動和前置作業時間延長的問題，這對傳統的採購方式提出了挑戰。這些關稅也適用於繁殖群和專用運輸路線，增加了物流成本，並要求更精準的預測。因此，研究預算面臨壓力，迫使相關人員重新調整業務優先級，並探索其他籌資策略。

發現深度細分模式，揭示研究類型、健康狀況、性別、最終用戶和疾病領域如何影響猴子研究的使用

依研究類型細分鼻咽癌臨床前市場，可以發現應用和資源分配的細微差別。藥效測試需要專門的免疫學檢測方法，以用於以生物製藥為重點的研究，而細胞療法研究則需要複雜的幹細胞追蹤和植入評估。相較之下，小分子的評估則主要依賴藥物動力學分析和代謝採樣。藥理學和致癌性研究進一步分為監測即時不利事件的急性毒性評估、旨在進行長期腫瘤風險評估的致癌性研究以及評估長期暴露結果的慢性毒性研究。作為這些臨床前安全性研究的補充，安全性評估工作流程結合了免疫抗原性測試以測量潛在的免疫反應，以及整合多器官系統分析的綜合臨床前安全性評估。

確定美洲、歐洲、中東和非洲以及亞太地區區域差異對臨床前試驗業務效率的影響

在美洲，完善的基礎設施和對監管協調的重視，為食蟹猴研究創造了成熟的環境。北美和中南美的機構受益於一體化的育種計畫和精簡的進口法規，確保了檢體的持續供應。這種營運穩定性支持嚴謹的研究規劃，並使研究機構能夠實施先進的自動化和數位化追蹤系統，從而提高數據完整性和測試可重複性。因此，研究機構可以最佳化資源配置，並更有信心確保計劃進度。

透過創新策略夥伴關係和先進的實驗室解決方案，發現影響臨床前研究的關鍵產業參與者

委外研發機構已成為食蟹猴臨床前研究的關鍵促進者。透過整合包括研究設計、體內試驗和法規支援在內的端到端服務，這些公司幫助申辦方加速其專案進程，同時遵守國際標準。他們致力於方法學創新，例如採用生物標記主導的終點和先進的成像技術，凸顯了他們致力於提供轉化數據以簡化臨床開發工作的重點。

為產業領導者提供實用建議和戰術性藍圖，以加強食蟹猴研究中的道德實踐和科學嚴謹性

鼓勵產業領導者採取循序漸進的方法來最佳化動物福利，首先要從模擬自然棲息地的綜合環境最佳化計畫著手。盡可能納入社會住宅並改善麻醉通訊協定，可以顯著減少與壓力相關的混雜因素。此外，投資定期培訓技術人員掌握操作技巧和行為評估，有助於創造更人性化的研究環境。將這些實踐納入標準操作程序，不僅能履行倫理義務，還能提高研究結果的可靠性。

結合主要相關人員參與、二手文獻分析和可靠資料檢驗的嚴格混合方法研究方法的細節

本研究採用混合方法，旨在全面洞察鴨嘴猴的臨床前應用。研究整合了主要相關人員的參與和全面的文獻分析，以確保研究結果符合時效性並反映行業實際挑戰。所有資料收集和分析通訊協定均經過精心設計，以促進三角檢驗，從而增強結論的有效性。研究始終遵循倫理道德準則，確保研究的透明度和完整性。

我們總結了主要結論，並強調了最佳化臨床前工作流程和加強倫理標準的積極機會

技術進步、監管格局演變和供應鏈動態的交匯，徹底改變了食蟹猴臨床前研究的格局。高保真疾病模型、精準的基因組分析工具以及完善的福利規程，共同提升了安全性和有效性評估的預測效度。同時，關稅相關的壓力凸顯了多元化採購和營運韌性的重要性。綜合來看，這些因素凸顯了策略敏捷性和協作創新至關重要的變革時期。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴大食蟹猴在神經科學和行為研究的應用
  • 食蟹猴在藥物毒性測試的應用日益增多
  • 加強食蟹猴研究領域的產學合作
  • 實驗食蟹猴非侵入性成像技術的開發
  • 人工智慧對食蟹猴實驗數據分析的影響
  • 實驗室食蟹猴飼養和護理標準的新趨勢
  • 越來越多的合約研究組織提供食蟹猴服務
  • 倫理法規對實驗室食蟹猴使用的影響
  • 基因工程技術在食蟹猴研究的進展
  • 生物醫學研究對實驗性食蟹猴模型的需求日益成長

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：美國關稅的累積影響（2025年）

8. 實驗室食蟹猴市場（依研究類型）

  • 藥物療效測試
    • 生物製藥
    • 細胞療法
    • 小分子藥物
  • 藥理學和毒理學研究
    • 急性毒性
    • 致癌性測試
    • 慢性毒性
  • 安全性評估
    • 免疫抗原性研究
    • 臨床前安全性評價
  • 疫苗檢測

9. 實驗室食蟹猴市場（依健康狀況）

  • 疾病模型
  • 基因突變
  • 健康食蟹猴

第10章 實驗室食蟹猴市場：性別

  • 女性
  • 男性

第 11 章。實驗室食蟹猴市場（按最終用戶）

  • 學術研究機構
  • 合約研究組織
  • 製藥和生物技術公司

12. 實驗食蟹猴市場（依治療領域）

  • 心血管研究
  • 遺傳學/基因組學研究
  • 免疫學研究
  • 感染疾病
  • 神經學研究
  • 腫瘤學研究
  • 呼吸系統疾病

13.美國實驗室食蟹猴市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14.歐洲、中東和非洲實驗室食蟹猴市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15.亞太實驗室食蟹猴市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 市場佔有率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Alpha Genesis, Inc.
    • AMSBIO by Europa Biosite
    • Athens Research & Technology, Inc.
    • BioChain Institute Inc.
    • BioChemed Services
    • BioIVT LLC
    • Cell Biologics, Inc.
    • Creative Biolabs, Inc.
    • Hainan Jingang Biotech.,Co.LTD.
    • Hubei Topgene Biotechnology Co., Ltd.
    • Innovative Research Inc.
    • iQ Biosciences
    • Lab Bioreagents
    • ODIN Bioscience
    • Primate Product Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-EF0BD2D829EA

The Experimental Cynomolgus Monkey Market was valued at USD 316.01 million in 2024 and is projected to grow to USD 336.11 million in 2025, with a CAGR of 6.59%, reaching USD 463.49 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 316.01 million
Estimated Year [2025] USD 336.11 million
Forecast Year [2030] USD 463.49 million
CAGR (%) 6.59%

Exploring the Critical Role of Cynomolgus Monkeys in Preclinical Research and Development to Advance Drug Discovery and Safety Assessment Pipelines

Preclinical evaluation using nonhuman primate models remains a cornerstone in ensuring the safety and efficacy of novel therapeutics. Among available species, Cynomolgus monkeys provide an unparalleled genetic and physiological resemblance to humans, enabling researchers to generate translational data that underpin clinical decision making. Their immunological response profiles mirror key aspects of human biology, making them indispensable in assessing biologics, cell based therapies, and small molecule drugs. Moreover, well established colony management practices and standardized testing protocols contribute to reproducible outcomes across laboratories globally.

As drug development paradigms shift towards targeted therapies and personalized medicine, the role of these primate models has expanded beyond traditional toxicology. Investigations into chronic toxicity, carcinogenicity assessments, and immunogenicity studies rely heavily on insights drawn from Cynomolgus subjects. Vaccine efficacy and safety testing further benefit from these models' susceptibility to human relevant pathogens, ensuring that candidate immunogens elicit appropriate protective responses. This broad spectrum of applications supports a comprehensive preclinical strategy, bridging in vitro findings with human clinical trials.

The growing complexity of therapeutic modalities and the rising stringency of regulatory frameworks have amplified demand for advanced animal models. Concurrently, evolving ethical standards emphasize refinement, reduction, and replacement strategies, challenging stakeholders to balance scientific rigor with humane practices. Against this backdrop, understanding the current landscape and emerging trends becomes essential for organizations to navigate operational and strategic decisions effectively.

Analyzing the Pivotal Technological and Regulatory Shifts That Are Redefining Cynomolgus Monkey Research and Accelerating Preclinical Innovation and Compliance

Innovative technologies and evolving regulatory policies are reshaping preclinical research paradigms, with Cynomolgus monkeys at the forefront of this transformation. Advances in gene editing tools such as CRISPR and precise genomic characterization are enabling the development of bespoke disease models, unlocking new avenues for therapeutic validation. Simultaneously, high resolution imaging techniques and in vivo telemetry facilitate real time monitoring of physiological responses, reducing reliance on traditional invasive methods. These breakthroughs not only enhance data quality but also underscore a commitment to more humane study designs.

Regulatory bodies are increasingly mandating rigorous welfare standards, mandating adoption of noninvasive endpoints, and promoting the three Rs principles-refinement, reduction, and replacement. In response, researchers are integrating digital twins and predictive modeling to anticipate outcomes, thereby optimizing study parameters and minimizing animal usage. Industry collaborations with contract research organizations and academic centers are accelerating standardization of protocols, ensuring consistency across geographies and strengthening data comparability for global regulatory submissions.

Furthermore, the integration of artificial intelligence and machine learning into data analytics pipelines is streamlining toxicity prediction, safety assessment, and decision making. As a result, study timelines are becoming more efficient, and resource allocation can be redirected toward innovative trial designs. Together, these technological and regulatory shifts are charting a new trajectory for Cynomolgus monkey research, fostering a landscape that is more ethical, precise, and aligned with the evolving demands of the biopharmaceutical industry.

Examining the Far Reaching Consequences of Recent United States Tariff Measures on Supply Chain Dynamics Research Costs and Regulatory Adaptations

The introduction of higher tariffs on imported nonhuman primate specimens has introduced a layer of complexity into preclinical study planning. Research organizations that historically relied on established supply chains have witnessed price volatility and prolonged lead times, challenging traditional procurement practices. These tariff measures have been applied to breeding colonies and specialized transportation channels, driving up logistical costs and necessitating more meticulous forecasting. As a result, research budgets are experiencing pressure, prompting stakeholders to reassess operational priorities and explore alternative sourcing strategies.

Supply chain disruptions have cascaded into breeding facility operations, where increased import costs are influencing colony management decisions. Some organizations are investing in local breeding capacities to mitigate dependency on international vendors, while others are forging strategic partnerships with regional suppliers to buffer against trade fluctuations. In parallel, contract research entities are adjusting service offerings to accommodate extended timelines and cost adjustments, ensuring continuity of studies without compromising scientific integrity. Moreover, interdisciplinary collaborations with regulatory affairs teams are facilitating compliance with complex tariff classifications, streamlining customs clearance, and reducing avoidable delays.

Looking ahead, the ongoing tariff environment is likely to stimulate innovation in supply chain resilience and cost optimization. Organizations that proactively diversify their vendor portfolios and implement digital tracking of specimen shipments are better positioned to absorb economic shocks. Equally important is the emphasis on regulatory intelligence, whereby continuous monitoring of policy changes enables timely adaptations and preserves critical research timelines. By navigating these evolving dynamics strategically, stakeholders can maintain momentum in preclinical development and safeguard the robustness of safety and efficacy assessments.

Uncovering Deep Segmentation Patterns That Reveal How Research Type Health Status Gender End User and Disease Area Shape Cynomolgus Monkey Study Applications

Segmenting the Cynomolgus monkey preclinical market by research type uncovers nuanced applications and resource allocations. Within drug efficacy testing, studies focusing on biologics demand specialized immunological assays, while cell therapy investigations necessitate advanced stem cell tracking and engraftment assessments. Small molecule evaluations, in contrast, lean heavily on pharmacokinetic profiling and metabolic sampling. Pharmacology and toxicology studies are further categorized into acute toxicity evaluations that monitor immediate adverse events, carcinogenicity tests designed for long term oncological risk assessment, and chronic toxicity investigations that assess extended exposure outcomes. Complementing these preclinical safety studies, safety assessment workflows incorporate immunogenicity studies to gauge potential immune responses, alongside comprehensive preclinical safety evaluations that integrate multi organ system analyses.

Health status segmentation further differentiates study design, as disease models replicate pathophysiological conditions to validate therapeutic interventions, and genetic variant cohorts enable exploration of gene therapy safety and efficacy. Parallel investigations involving healthy Cynomolgus subjects provide baseline comparative data. Gender considerations address biological variability, with female and male subjects offering critical insights into sex specific pharmacodynamics and toxicity profiles. These distinct segmentation lenses inform the design of robust experimental protocols that capture diverse biological responses.

End user segmentation reveals a spectrum of institutional needs. Academic and research institutes emphasize methodological transparency and hypothesis driven studies, while contract research organizations prioritize scalable workflows and regulatory compliance services. Pharmaceutical and biotechnology companies seek integrated end to end solutions and deep domain expertise. Overlaying these user focused perspectives is disease area segmentation, where cardiovascular studies leverage hemodynamic monitoring platforms, genetic and genomic research employs targeted sequencing approaches, immunology investigations rely on flow cytometry panels, infectious disease protocols simulate pathogen exposure, neurological research demands sophisticated behavioral and cognitive assessments, oncology research integrates tumor xenograft models, and respiratory disease studies utilize inhalation challenge systems to evaluate pulmonary function.

Distilling Critical Regional Variations Across the Americas Europe Middle East Africa and Asia Pacific That Influence Preclinical Trial Operational Efficiency

In the Americas, established infrastructure and a strong emphasis on regulatory harmonization have cultivated a mature environment for Cynomolgus monkey research. North American and Latin American facilities benefit from consolidated breeding programs and streamlined import regulations, fostering consistent specimen availability. This operational stability supports rigorous study planning and allows institutions to implement advanced automation and digital tracking systems, which enhance data integrity and trial reproducibility. Consequently, organizations can optimize resource allocation and maintain project timelines with greater confidence.

Europe, Middle East, and Africa present a diverse landscape characterized by varying degrees of regulatory complexity and breeding capacity. Western European markets are renowned for their strict ethical oversight and adherence to the three Rs principles, promoting the adoption of refined methodologies and noninvasive endpoints. In contrast, regions within the Middle East and parts of Africa are experiencing burgeoning investments in preclinical infrastructure, often through public private partnerships. These emerging hubs offer opportunities for cost effective sourcing and collaborative research initiatives, although stakeholders must navigate heterogeneous regulatory frameworks to ensure compliance.

Asia Pacific exhibits dynamic growth driven by substantial investment in biotechnology and contract research sectors. Countries such as China, Japan, and Singapore are expanding breeding capacities and establishing world class facilities that emphasize both animal welfare and scientific rigor. Regulatory agencies are progressively aligning with international standards, facilitating cross border collaborations and sample exchange. Moreover, regional expertise in specialized disease models and high throughput screening has attracted global sponsors seeking efficient and scalable preclinical solutions. Adaptation to local logistical challenges, including transport and quarantine protocols, underscores the importance of strategic partnerships to realize operational efficiency and study continuity.

Illuminating Major Industry Players Shaping Cynomolgus Monkey Preclinical Research Through Innovation Strategic Partnerships and Advanced Laboratory Solutions

Leading global contract research organizations have established themselves as pivotal drivers of Cynomolgus monkey based preclinical work. By integrating end to end services that encompass study design, in vivo testing, and regulatory submission support, these firms enable sponsors to accelerate programs while maintaining compliance with international standards. Their commitment to methodological innovation, such as implementing biomarker driven endpoints and advanced imaging modalities, underscores a focus on delivering translational data that can streamline clinical development.

Key breeding and supply entities have complemented CRO operations by scaling proprietary colony management systems and ensuring traceable pedigrees. These organizations emphasize biosecurity protocols, genetic monitoring, and health surveillance to guarantee specimen quality. Their investments in geographically dispersed facilities also mitigate supply chain disruptions, offering researchers alternative sourcing options that align with ethical and welfare guidelines. Collaboration between breeders and research providers has enhanced transparency across the supply continuum.

Specialized technology providers and academic consortia contribute to the ecosystem by developing novel disease models, analytical platforms, and data management solutions. Partnerships between research institutes, pharmaceutical sponsors, and service providers have resulted in shared resources and harmonized best practices. Moreover, strategic alliances aimed at refining noninvasive techniques and digital data integration are fostering a new generation of preclinical protocols. Together, these industry players drive continuous improvement in study quality, operational efficiency, and ethical compliance.

Delivering Pragmatic Recommendations and Tactical Roadmaps for Industry Leaders to Enhance Ethical Practices and Scientific Rigor in Cynomolgus Monkey Studies

Industry leaders are encouraged to adopt a tiered approach to welfare optimization, beginning with comprehensive environmental enrichment programs that mimic natural habitats. Incorporating social housing where feasible and refining anesthesia protocols can significantly reduce stress related confounders. Additionally, investing in regular training for technical staff on handling techniques and behavioral assessment contributes to more humane study conditions. Embedding these practices into standard operating procedures not only fulfills ethical obligations but can enhance the reliability of research outcomes.

To improve operational efficiency, organizations should prioritize the integration of real time data capture and laboratory information management systems. Automated workflows that streamline sample tracking, inventory management, and protocol execution reduce manual errors and accelerate study timelines. Furthermore, establishing robust vendor diversification strategies and leveraging regional breeding capacities can mitigate supply chain risks and control costs. Proactive regulatory intelligence efforts ensure swift adaptation to policy changes and customs requirements, maintaining study continuity.

Enhancing scientific rigor requires the adoption of advanced analytical methodologies and statistical frameworks that address biological variability. Cross sector collaborations can foster the development of harmonized endpoints and reference databases, enabling comparative analyses across studies. Embracing digital modeling and machine learning to augment in vivo findings can refine dose selection and safety thresholds. By aligning organizational objectives with these recommendations, leaders can drive transformative improvements in both the quality and ethical integrity of preclinical research.

Detailing a Rigorous Mixed Methodology Combining Primary Stakeholder Engagement Secondary Literature Analysis and Robust Data Validation

This research initiative employed a mixed methodology designed to deliver comprehensive insights into Cynomolgus monkey preclinical applications. By integrating primary stakeholder engagement with exhaustive literature analysis, the approach ensured that findings were both current and reflective of practical industry challenges. All data collection and analysis protocols were structured to facilitate triangulation, thereby enhancing the validity of conclusions drawn. Ethical considerations were applied throughout to maintain transparency and integrity.

Primary research involved structured interviews and consultations with domain experts across contract research organizations, pharmaceutical developers, academic institutions, and regulatory agencies. Each discussion was guided by a predefined framework to explore technological trends, operational challenges, and policy implications. Responses were systematically recorded, coded, and thematically analyzed to identify recurring patterns and divergent perspectives. This iterative process allowed for continuous refinement of inquiry areas and validated emerging insights through stakeholder feedback loops.

Secondary research encompassed an extensive review of peer reviewed studies, industry white papers, regulatory guidelines, and proprietary reports. Data points related to animal welfare standards, assay validation techniques, and preclinical pipeline strategies were extracted and consolidated into a dynamic knowledge base. Rigorous data validation procedures were applied, including cross referencing multiple information sources and conducting consistency checks. Throughout the methodology, quality control measures were implemented to ensure methodological rigor and to support actionable recommendations grounded in a robust evidence base.

Synthesizing Key Conclusions and Highlighting Forward Looking Opportunities to Optimize Preclinical Workflows and Enhance Ethical Standards

The convergence of technological advancements, regulatory evolution, and supply chain dynamics has fundamentally reshaped the landscape of Cynomolgus monkey preclinical research. High fidelity disease models, precision genomic tools, and refined welfare protocols are collectively elevating the predictive validity of safety and efficacy assessments. Meanwhile, tariff related pressures have underscored the importance of diversified sourcing and operational resilience. Taken together, these factors highlight a transformative period in which strategic agility and collaborative innovation are essential.

Looking forward, opportunities exist to expand the role of digital twins and in silico modeling as complementary approaches that reduce reliance on live subjects. Investment in noninvasive monitoring tools, such as wearable biosensors and advanced imaging, promises to augment traditional endpoints while adhering to the three Rs principles. Additionally, deeper integration of data analytics and artificial intelligence can optimize study design, automate anomaly detection, and accelerate decision making. Cross sector consortia are poised to harmonize data standards, facilitating seamless multistudy comparisons and benchmarking.

By embracing these forward looking strategies, organizations can not only advance their preclinical programs but also contribute to a more ethical and efficient research paradigm. The trajectory of Cynomolgus monkey studies will be defined by the collective commitment to scientific excellence, animal welfare, and regulatory compliance. As the industry continues to evolve, stakeholders that proactively adopt these insights will be best positioned to lead the next generation of translational research initiatives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expanding use of Cynomolgus monkeys in neuroscience and behavioral research
  • 5.2. Rising adoption of Cynomolgus monkeys in pharmaceutical drug toxicity testing
  • 5.3. Increasing collaboration between academic institutions and industry in Cynomolgus monkey research
  • 5.4. Developments in non-invasive imaging techniques for experimental Cynomolgus monkeys
  • 5.5. Influence of artificial intelligence on data analysis in Cynomolgus monkey experiments
  • 5.6. Emerging trends in housing and care standards for experimental Cynomolgus monkeys
  • 5.7. Growth of contract research organizations providing Cynomolgus monkey services
  • 5.8. Impact of ethical regulations on the use of experimental Cynomolgus monkeys
  • 5.9. Advancements in genetic engineering techniques for Cynomolgus monkey studies
  • 5.10. Increasing demand for experimental Cynomolgus monkey models in biomedical research

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Experimental Cynomolgus Monkey Market, by Research Type

  • 8.1. Introduction
  • 8.2. Drug Efficacy Testing
    • 8.2.1. Biologics
    • 8.2.2. Cell Therapies
    • 8.2.3. Small Molecule Drugs
  • 8.3. Pharmacology & Toxicology Studies
    • 8.3.1. Acute Toxicity
    • 8.3.2. Carcinogenicity Tests
    • 8.3.3. Chronic Toxicity
  • 8.4. Safety Assessment
    • 8.4.1. Immunogenicity Studies
    • 8.4.2. Preclinical Safety Evaluation
  • 8.5. Vaccine Testing

9. Experimental Cynomolgus Monkey Market, by Health Status

  • 9.1. Introduction
  • 9.2. Disease Models
  • 9.3. Genetic Variants
  • 9.4. Healthy Cynomolgus Monkeys

10. Experimental Cynomolgus Monkey Market, by Gender

  • 10.1. Introduction
  • 10.2. Female
  • 10.3. Male

11. Experimental Cynomolgus Monkey Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Experimental Cynomolgus Monkey Market, by Disease Area

  • 12.1. Introduction
  • 12.2. Cardiovascular Studies
  • 12.3. Genetic / Genomic Research
  • 12.4. Immunology Research
  • 12.5. Infectious Diseases
  • 12.6. Neurological Research
  • 12.7. Oncology Research
  • 12.8. Respiratory Diseases

13. Americas Experimental Cynomolgus Monkey Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Experimental Cynomolgus Monkey Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Experimental Cynomolgus Monkey Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alpha Genesis, Inc.
    • 16.3.2. AMSBIO by Europa Biosite
    • 16.3.3. Athens Research & Technology, Inc.
    • 16.3.4. BioChain Institute Inc.
    • 16.3.5. BioChemed Services
    • 16.3.6. BioIVT LLC
    • 16.3.7. Cell Biologics, Inc.
    • 16.3.8. Creative Biolabs, Inc.
    • 16.3.9. Hainan Jingang Biotech.,Co.LTD.
    • 16.3.10. Hubei Topgene Biotechnology Co., Ltd.
    • 16.3.11. Innovative Research Inc.
    • 16.3.12. iQ Biosciences
    • 16.3.13. Lab Bioreagents
    • 16.3.14. ODIN Bioscience
    • 16.3.15. Primate Product Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET: RESEARCHAI
  • FIGURE 26. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET: RESEARCHCONTACTS
  • FIGURE 28. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY ACUTE TOXICITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY ACUTE TOXICITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CARCINOGENICITY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CARCINOGENICITY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CHRONIC TOXICITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CHRONIC TOXICITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY IMMUNOGENICITY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY IMMUNOGENICITY STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PRECLINICAL SAFETY EVALUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PRECLINICAL SAFETY EVALUATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY VACCINE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY VACCINE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE MODELS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENETIC VARIANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENETIC VARIANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTHY CYNOMOLGUS MONKEYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTHY CYNOMOLGUS MONKEYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY FEMALE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY MALE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CARDIOVASCULAR STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY CARDIOVASCULAR STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENETIC / GENOMIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENETIC / GENOMIC RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY IMMUNOLOGY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY IMMUNOLOGY RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY NEUROLOGICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY NEUROLOGICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 150. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 163. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 166. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 177. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 178. ARGENTINA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED KINGDOM EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 213. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 216. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 217. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 218. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 227. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 228. GERMANY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 229. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 232. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 233. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 234. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 235. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 236. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 243. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 244. FRANCE EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 245. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 248. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 249. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 250. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 251. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 252. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 253. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 254. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 259. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 261. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 264. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 265. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 266. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 267. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 268. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 269. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 270. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 271. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 272. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 273. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 275. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 276. ITALY EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 277. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 280. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2025-2030 (USD MILLION)
  • TABLE 281. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2018-2024 (USD MILLION)
  • TABLE 282. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY PHARMACOLOGY & TOXICOLOGY STUDIES, 2025-2030 (USD MILLION)
  • TABLE 283. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 284. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY SAFETY ASSESSMENT, 2025-2030 (USD MILLION)
  • TABLE 285. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY HEALTH STATUS, 2025-2030 (USD MILLION)
  • TABLE 287. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
  • TABLE 289. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 291. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED ARAB EMIRATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED ARAB EMIRATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY RESEARCH TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED ARAB EMIRATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TESTING, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED ARAB EMIRATES EXPERIMENTAL CYNOMOLGUS MONKEY MARKET SIZE, BY DRUG EFFICACY TEST